[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL: 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med; 2009 Aug;50(8):1237-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
  • The purpose of this study was to compare the diagnostic utility of (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (18)F-FDG PET in neuroblastoma.
  • METHODS: A total of 113 paired (123)I-MIBG and (18)F-FDG PET scans in 60 patients with neuroblastoma were retrospectively reviewed.
  • RESULTS: For stage 1 and 2 neuroblastoma (13 scans, 10 patients), (18)F-FDG depicted more extensive primary or residual neuroblastoma in 9 of 13 scans. (123)I-MIBG and (18)F-FDG showed equal numbers of lesions in 1 of 13 scans, and 3 of 13 scan results were normal.
  • For stage 3 neuroblastoma (15 scans, 10 patients), (123)I-MIBG depicted more extensive primary neuroblastoma or local or regional metastases in 5 of 15 scans. (18)F-FDG depicted more extensive primary neuroblastoma or local or regional metastases in 4 of 15 scans. (123)I-MIBG and (18)F-FDG were equal in 2 of 15 scans, and 4 of 15 scan results were normal.
  • For stage 4 neuroblastoma (85 scans, 40 patients), (123)I-MIBG depicted more neuroblastoma sites in 44 of 85 scans. (18)F-FDG depicted more neuroblastoma sites in 11 of 85 scans. (123)I-MIBG and (18)F-FDG were equivalent or complementary in 13 of 85 scans, and 17 of 85 scan results were normal.
  • CONCLUSION: (18)F-FDG is superior in depicting stage 1 and 2 neuroblastoma, although (123)I-MIBG may be needed to exclude higher-stage disease. (18)F-FDG also provides important information for patients with tumors that weakly accumulate (123)I-MIBG and at major decision points during therapy (i.e., before stem cell transplantation or before surgery). (18)F-FDG can also better delineate disease extent in the chest, abdomen, and pelvis. (123)I-MIBG is overall superior in the evaluation of stage 4 neuroblastoma, especially during initial chemotherapy, primarily because of the better detection of bone or marrow metastases.
  • [MeSH-major] 3-Iodobenzylguanidine. Fluorodeoxyglucose F18. Neuroblastoma / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2010 Feb;51(2):330-1; author reply 331 [20080890.001]
  • [CommentIn] J Nucl Med. 2010 Feb;51(2):330; author reply 331 [20080883.001]
  • (PMID = 19617326.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


2. Mora J, Cheung NK, Gerald WL: Genetic heterogeneity and clonal evolution in neuroblastoma. Br J Cancer; 2001 Jul 20;85(2):182-9
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic heterogeneity and clonal evolution in neuroblastoma.
  • Tumour heterogeneity and clonal evolution at the genetic level may explain the development of malignant or resistant disease during clinical progression of neuroblastoma (NB).
  • 33 tumours from 12 patients (group 1) were obtained from different sites during the same surgery or at sequential surgeries without intervening chemotherapy to evaluate genetic heterogeneity.
  • Paired samples from 10 patients (group 2) were used to evaluate clonal selection before and after chemotherapy.
  • Analysis of DNA ploidy changes by karyotype, FISH and flow cytometry was performed in 15 tumours from 6 multiply recurred local-regional (LR) NB patients.
  • Allelotype study revealed that 66% (8/12) of group 1 samples were heterogeneous, with distinct allelic patterns in tumour samples separated by time or location.
  • In group 2 allelic patterns were different in post-chemotherapy specimens in 60% (6/10).
  • DNA ploidy analysis showed that pre-chemotherapy samples contained 2 distinct ploidy clones, one diploid and one triploid, whereas all post-chemotherapy tumor samples were 100% diploid.
  • These findings suggest that NB exhibits a high degree of clonal heterogeneity and clonal evolution occurs during the course of therapy and clinical progression.
  • [MeSH-major] Evolution, Molecular. Neuroblastoma / genetics

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4082-90 [9307297.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):176-7 [9149754.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):349-63 [10421272.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):435-42 [11180092.001]
  • [Cites] J Mol Diagn. 2000 Feb;2(1):37-46 [11272900.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):227-30 [11464891.001]
  • [Cites] J Natl Cancer Inst. 1984 Aug;73(2):405-16 [6589432.001]
  • [Cites] Cancer Res. 1987 Aug 15;47(16):4248-53 [2440561.001]
  • [Cites] Cancer. 1988 Aug 15;62(4):749-54 [3395958.001]
  • [Cites] Cytometry. 1989 May;10(3):229-41 [2653738.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9871-5 [7937908.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2607-13 [7527454.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5681-6 [7585654.001]
  • [Cites] Eur J Cancer. 1995;31A(4):505-10 [7576954.001]
  • [Cites] Eur J Cancer. 1995;31A(4):510-5 [7576955.001]
  • [Cites] N Engl J Med. 1996 Jun 6;334(23):1505-11 [8618605.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):42-9 [9591633.001]
  • (PMID = 11461074.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2364052
  •  go-up   go-down


3. Laprie A, Michon J, Hartmann O, Munzer C, Leclair MD, Coze C, Valteau-Couanet D, Plantaz D, Carrie C, Habrand JL, Bergeron C, Chastagner P, Défachelles AS, Delattre O, Combaret V, Bénard J, Pérel Y, Gandemer V, Rubie H, Neuroblastoma Study Group of the French Society of Pediatric Oncology: High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification. Cancer; 2004 Sep 1;101(5):1081-9
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
  • BACKGROUND: The objective of this study was to determine whether systemic and regional, intensified treatment can improve the outcome of children who present with a localized neuroblastoma (NB) with MYCN amplification (MNA).
  • METHODS: Between 1990 and 2000, 610 children with localized NB were included in the Localized Neuroblastoma 90 (NBL 90) and NBL 94 study from the French Society of Pediatric Oncology.
  • During the first period of the study, 20 children (Group A) received postoperative conventional chemotherapy (CT) and/or radiotherapy (RT), depending on each patient's postoperative status.
  • RESULTS: The two groups were comparable with regard to prognostic factors (age, location of the primary lesion, International Neuroblastoma Staging System stage, lymph node invasion) and response to preoperative CT.
  • CONCLUSIONS: Postoperative intensification treatment with HDC, SCR, and locoregional RT resulted in higher survival rates when compared with standard treatment alone and should be considered in the treatment plan for children who are diagnosed with Stage II or III NB and MYCN amplification.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Amplification. Genes, myc. Neuroblastoma / genetics. Neuroblastoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Gamma Rays. Humans. Infant. Infant, Newborn. Lymph Nodes / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Postoperative Care. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15329919.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR: Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer; 2004 Mar 15;100(6):1268-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
  • BACKGROUND: The optimal administration of radiotherapy for patients with high-risk neuroblastoma (NB) currently is undefined in the context of modern therapy using myeloablative chemotherapy with autologous stem cell rescue (hematopoietic stem cell transplantation [HSCT]).
  • Therapy included multiagent induction chemotherapy and delayed surgical resection, consolidation of HSCT and local XRT, and 13-cis-retinoic acid maintenance therapy.
  • The median time to XRT post-HSCT was 54 days.
  • CONCLUSIONS: Post-HSCT, fractionated XRT to 2100 cGy was a tolerable and effective treatment for patients with high-risk NB, and minimal recurrences were observed at designated XRT sites.
  • [MeSH-major] Dose Fractionation. Hematopoietic Stem Cell Transplantation. Neuroblastoma / mortality. Neuroblastoma / therapy. Radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Treatment Outcome


5. Kushner BH, Kramer K, LaQuaglia MP, Cheung NK: Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy. J Pediatr Hematol Oncol; 2003 Jul;25(7):515-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy.
  • PURPOSE: A reluctance to treat local-regional neuroblastoma by surgery alone derives partly from concern that if widespread neuroblastoma develops, the chance for cure is small, and partly from hope that mild chemotherapy will prevent relapse.
  • The authors report on a series of patients who had distant recurrences after surgery alone for local-regional neuroblastoma.
  • METHODS: Seven patients treated with surgery alone for local-regional neuroblastoma had widespread relapses 2.5 to 25 (median 7) months later and were treated at Memorial Sloan-Kettering Cancer Center (MSKCC).
  • During the period of this study (1995-1999), MSKCC patients with high-risk neuroblastoma received the N7 protocol (dose-intensive chemotherapy, immunotherapy with the anti-G(D2) 3F8 antibody, targeted radiotherapy using 131I-3F8, local radiotherapy) if they had assessable disease, or 3F8 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by 13-cis-retinoic acid if they were in remission after treatment elsewhere.
  • RESULTS: Five patients were in complete remission 3 years 11 months to 7 years 4 months from the start of retrieval therapy, including three who received all of their N7 treatment of relapsed neuroblastoma at MSKCC, one who received two cycles of chemotherapy elsewhere before starting N7, and one who was referred for 3F8/GM-CSF because of neuroblastoma cells in pretransplantation bone marrow.
  • CONCLUSIONS: The encouraging survival results of our cohort are consistent with the concept that surgery alone for local-regional neuroblastoma might be beneficial to the overall neuroblastoma population because many patients will never need chemotherapy (and will therefore be spared its potential toxicities), and most of those who do have widespread relapses are likely to be cured with contemporary treatments.
  • [MeSH-major] Immunotherapy. Neuroblastoma / surgery. Neuroblastoma / therapy
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Female. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Humans. Infant. Iodine Radioisotopes / therapeutic use. Male. Prognosis. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2003 Jul;25(7):512-4 [12847315.001]
  • (PMID = 12847316.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61017; United States / NCI NIH HHS / CA / CA72868
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Recombinant Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


6. Monclair T: [Surgical treatment of solid malignant tumours in childhood]. Tidsskr Nor Laegeforen; 2006 Sep 21;126(18):2380-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of solid malignant tumours in childhood].
  • [Transliterated title] Kirurgisk behandling av solide maligne barnesvulster.
  • BACKGROUND: Surgery is an important part of the multidisciplinary treatment of solid malignant tumours in childhood.
  • This article gives an update on the types and numbers of tumour operations in Paediatric Surgical Service, Department of Surgery, Rikshospitalet.
  • The presentation is restricted to the surgical part of the treatment; data on chemotherapy and irradiation are not included.
  • 58% of the patients came from the regional health enterprise for southern Norway, where Rikshospitalet is located, and 42% came from the other 4 Norwegian health regions.
  • Since 1993, 30 of 203 patients have been referred from the other 4 regional hospitals.
  • The survival rates for the individual tumours ranged from 100% for ovarian tumours and 98% for Wilms' tumour to 62% for neuroblastoma.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998551.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


7. Selle B, Furtwängler R, Graf N, Kaatsch P, Bruder E, Leuschner I: Population-based study of renal cell carcinoma in children in Germany, 1980-2005: more frequently localized tumors and underlying disorders compared with adult counterparts. Cancer; 2006 Dec 15;107(12):2906-14
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The characteristics of RCC-affected children and their tumors, the influence of treatment, and outcome have so far not been studied in a nonselected, population-based cohort.
  • In about every third child possibly RCC-related underlying disorders (tuberous sclerosis, neuroblastoma, teratoma with chemotherapy, Saethre-Chotzen syndrome, chronic renal failure) or related diseases in their family were found.
  • The pathologic subtypes were papillary in 16 (33%), translocation type in 11 (22%), unclassified in 8 (16%), and rarely clear-cell (n = 3) or others.
  • Thirty-four (69%) patients had localized RCC, 8 (16%) patients regional lymph node metastases, and 4 (8%) patients distant metastases.
  • Event-free survival and overall survival rates at 5 years were 96% for localized RCC, 69% and 75% for regional lymph node-positive, 25% and 33% for distant metastatic RCC, respectively.
  • Two of 4 patients with distant metastases received immunotherapy combined with chemotherapy and surgery, both are alive, 1 of them disease-free for 6.9 years.
  • Survival rates in localized and regional lymph node-positive cases are favorable.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Female. Germany. Humans. Infant. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 17109448.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest; 2000 Apr;105(8):R15-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
  • Various conventional chemotherapeutic drugs can block angiogenesis or even kill activated, dividing endothelial cells.
  • Such effects may contribute to the antitumor efficacy of chemotherapy in vivo and may delay or prevent the acquisition of drug-resistance by cancer cells.
  • We have implemented a treatment regimen that augments the potential antivascular effects of chemotherapy, that is devoid of obvious toxic side effects, and that obstructs the development of drug resistance by tumor cells.
  • Xenografts of 2 independent neuroblastoma cell lines were subjected to either continuous treatment with low doses of vinblastine, a monoclonal neutralizing antibody (DC101) targeting the flk-1/KDR (type 2) receptor for VEGF, or both agents together.
  • The rationale for this combination was that any antivascular effects of the low-dose chemotherapy would be selectively enhanced in cells of newly formed vessels when survival signals mediated by VEGF are blocked.
  • Both DC101 and low-dose vinblastine treatment individually resulted in significant but transient xenograft regression, diminished tumor vascularity, and direct inhibition of angiogenesis.
  • Remarkably, the combination therapy resulted in full and sustained regressions of large established tumors, without an ensuing increase in host toxicity or any signs of acquired drug resistance during the course of treatment, which lasted for >6 months.

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • American Type Culture Collection. culture/stock collections - ATCC HB-11534 (subscription/membership/fee required).
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2289-96 [10499595.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):411-6 [10501915.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3964-72 [10406801.001]
  • [Cites] Pediatrics. 1999 Jun;103(6 Pt 1):1145-9 [10353921.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5209-18 [10537299.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2669-71 [10537326.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):781-8 [10544009.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1359-64 [10581076.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4143-55 [10590059.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5875-7 [10606226.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):393-8 [10666367.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Cancer Res. 1970 Oct;30(10):2470-6 [4097429.001]
  • [Cites] Cancer Res. 1972 Jan;32(1):77-82 [5007690.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(3):187-92 [2544308.001]
  • [Cites] Arthritis Rheum. 1989 Sep;32(9):1065-73 [2476134.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1577-82 [2507122.001]
  • [Cites] Cancer Metastasis Rev. 1990 Nov;9(3):253-66 [2292138.001]
  • [Cites] Eur J Cancer. 1991;27(4):482-7 [1827725.001]
  • [Cites] Bioessays. 1991 Jan;13(1):31-6 [1722975.001]
  • [Cites] EXS. 1992;61:449-54 [1377570.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6702-4 [1384969.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):519-28 [1279270.001]
  • [Cites] Br J Radiol. 1993 Mar;66(783):181-96 [7682469.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5036-40 [7923112.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1024-8 [7489357.001]
  • [Cites] Lab Invest. 1995 Dec;73(6):844-50 [8558846.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2417-26 [8823319.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14765-70 [8962129.001]
  • [Cites] Invest New Drugs. 1997;15(1):39-48 [9195288.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2072-8 [9329972.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Nature. 1997 Nov 27;390(6658):404-7 [9389480.001]
  • [Cites] Kobe J Med Sci. 1997 Aug;43(3-4):109-20 [9489296.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1331-6 [9607594.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2164-8 [9626217.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):287-91 [9685160.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10820-5 [9724788.001]
  • [Cites] Cancer Metastasis Rev. 1998 Jun;17(2):155-61 [9770111.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1843-9 [9816139.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):99-106 [9892193.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):181-7 [9918217.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):159-65 [9916127.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):375-84 [10027396.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2417-24 [10344752.001]
  • [CommentIn] J Clin Invest. 2000 Apr;105(8):1045-7 [10772648.001]
  • [ErratumIn] J Clin Invest. 2006 Nov;116(11):3084
  • [ErratumIn] J Clin Invest. 2006 Oct;116(10):2827
  • (PMID = 10772661.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA041233; United States / NCI NIH HHS / CA / CA-41233
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Receptors, Growth Factor; 5V9KLZ54CY / Vinblastine; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ PMC517491
  •  go-up   go-down


9. Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, Cheung NK: Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol; 2001 Jun 01;19(11):2821-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery.
  • PURPOSE: To assess prognostic factors for local control in high-risk neuroblastoma patients treated with hyperfractionated 21-Gy total dose to consolidate remission achieved by dose-intensive chemotherapy and surgery.
  • PATIENTS AND METHODS: Patients with high-risk neuroblastoma in first remission received local radiotherapy (RT) totaling 21 Gy in twice-daily 1.5-Gy fractions.
  • RT to the primary site followed dose-intensive chemotherapy and tumor resection; the target field encompassed the extent of tumor at diagnosis, plus 3-cm margins and regional lymph nodes.
  • Local failure was correlated with clinical factors (including other consolidative treatments) and biologic findings.
  • CONCLUSION: Hyperfractionated 21-Gy RT is well tolerated and, together with dose-intensive chemotherapy and surgery, may help in local control of high-risk neuroblastoma.
  • Extending the RT field to definitively encompass regional nodal groups may improve results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroblastoma / radiotherapy
  • [MeSH-minor] Child, Preschool. Dose Fractionation. Female. Genes, myc. Humans. Infant. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11387353.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61017; United States / NCI NIH HHS / CA / CA72868
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


10. Davidoff AM, Corey BL, Hoffer FA, Santana VM, Furman WL, Shochat SJ: Radiographic assessment of resectability of locoregional disease in children with high-risk neuroblastoma during neoadjuvant chemotherapy. Pediatr Blood Cancer; 2005 Feb;44(2):158-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic assessment of resectability of locoregional disease in children with high-risk neuroblastoma during neoadjuvant chemotherapy.
  • BACKGROUND: The optimal timing for attempting removal of the primary tumor and regional disease in patients with high-risk neuroblastoma is uncertain.
  • The purpose of this study was to evaluate resectability of the primary tumor and regional disease, as determined radiographically, in children with high-risk neuroblastoma during neoadjuvant chemotherapy.
  • PROCEDURE: Patients enrolled in our institutional high-risk neuroblastoma protocol were evaluated prospectively by CT scan and/or MRI to determine the resectability of their primary tumor and regional disease at diagnosis, after two cycles of experimental therapy and after standard induction therapy.
  • RESULTS: Twenty-four patients were referred prior to surgery for treatment of high-risk neuroblastoma.
  • Seven of 24 (29%) patients were felt to be resectable at diagnosis, with an additional 9 patients becoming resectable after the initial experimental therapy.
  • Thus, overall, 16 of 24 (67%) patients were felt to be resectable by the completion of the initial therapy.
  • Only four additional patients of the remaining eight were considered resectable after the completion of standard induction therapy.
  • CONCLUSIONS: Based on these data, we conclude that complete resection of the primary tumor and regional disease in children with high-risk neuroblastoma can be performed after an initial phase therapy in the majority of patients.
  • Since earlier tumor removal may decrease the chance for the subsequent development of chemotherapy-resistant disease, we are recommending surgical resection as soon as the locoregional disease appears to be resectable.
  • [MeSH-major] Neuroblastoma / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Humans. Infant. Infant, Newborn. Neoadjuvant Therapy. Nuclear Proteins / genetics. Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15481078.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins
  •  go-up   go-down


11. Arnold DE, Gagne C, Niknejad N, McBurney MW, Dimitroulakos J: Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP. Mol Cell Biochem; 2010 Dec;345(1-2):1-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP.
  • Differentiation-based therapeutics are an underutilized but a potentially significant treatment option for cancer patients.
  • We used embryonal carcinoma (EC) and neuroblastoma (NB) cell lines and found that lovastatin promoted apoptosis and induced expression of the neuronal differentiation markers, tyrosine hydroxylase (TH), and growth-associated protein 43.
  • The apoptotic and differentiation responses were time and dose-dependant and rescued by the co-administration of mevalonate.
  • The expression of TH is regulated primarily by a cyclic AMP (cAMP) response element (CRE) in its promoter.
  • Furthermore, combining lovastatin with 1 mM dibutyryladenosine 3',5'-cyclic monophosphate treatments induced higher expression from the CRE construct, enhanced differentiation and cytotoxicity.
  • This study suggests the potential of combining these therapeutic approaches in EC and NB patients.
  • [MeSH-major] Apoptosis / drug effects. Bucladesine / pharmacology. Carcinoma, Embryonal / drug therapy. Cell Differentiation / drug effects. Lovastatin / pharmacology. Neuroblastoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Cyclic AMP / genetics. Drug Synergism. Drug Therapy, Combination. Humans. Response Elements / drug effects. Tumor Cells, Cultured. Tyrosine 3-Monooxygenase / genetics

  • Genetic Alliance. consumer health - Embryonal Carcinoma.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2002 Aug;7(4):321-8 [12101391.001]
  • [Cites] Nature. 1990 Feb 1;343(6257):425-30 [1967820.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;968:22-36 [12119265.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):248-56 [16828305.001]
  • [Cites] J Cell Physiol. 1998 Jul;176(1):50-6 [9618144.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):29748-56 [17699156.001]
  • [Cites] FEBS Lett. 2001 Jul 27;502(1-2):57-62 [11478948.001]
  • [Cites] Biochem Cell Biol. 2001;79(3):253-66 [11467739.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3021-6 [12843138.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):483-91 [9816194.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):167-78 [11426618.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1353-9 [18418074.001]
  • [Cites] Development. 2001 Feb;128(4):541-50 [11171337.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):337-46 [12082550.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):93-101 [9149737.001]
  • [Cites] Vet Comp Oncol. 2008 Mar;6(1):1-18 [19178659.001]
  • [Cites] Med Hypotheses. 2005;65(6):1202-3 [16084667.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Urol. 2003 Apr;169(4):1229-33 [12629333.001]
  • [Cites] Curr Opin Hematol. 2009 Mar;16(2):84-91 [19468269.001]
  • [Cites] J Neurosci. 2002 May 1;22(9):3543-52 [11978831.001]
  • [Cites] Genes Dev. 1996 Nov 15;10 (22):2903-11 [8918891.001]
  • [Cites] Cell Growth Differ. 1994 Apr;5(4):373-84 [8043511.001]
  • [Cites] J Neurooncol. 1999 Mar;42(1):1-11 [10360474.001]
  • [Cites] Future Oncol. 2009 Feb;5(1):33-42 [19243296.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S22-6 [11684438.001]
  • [Cites] Cell. 1994 Apr 22;77(2):175-8 [8168127.001]
  • [Cites] Brain Res Mol Brain Res. 1990 Jul;8(2):93-8 [1976199.001]
  • [Cites] J Neurochem. 2004 Apr;89(1):168-78 [15030401.001]
  • [Cites] J Cell Sci. 2001 Jul;114(Pt 13):2363-73 [11559745.001]
  • [Cites] Eur J Endocrinol. 1998 Dec;139(6):571-2 [9916858.001]
  • [Cites] Trends Genet. 1998 May;14 (5):178-83 [9613201.001]
  • [Cites] J Neurosci. 1999 Jun 1;19(11):4484-97 [10341249.001]
  • [Cites] Nature. 1982 Sep 9;299(5879):165-7 [7110336.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):158-67 [11205904.001]
  • [Cites] Mol Cell Neurosci. 2004 Mar;25(3):536-47 [15033181.001]
  • [Cites] Pharmacol Res. 1995 Jan;31(1):9-27 [7784310.001]
  • [Cites] FEBS Lett. 1993 Apr 5;320(2):150-4 [8096193.001]
  • [Cites] J Am Coll Cardiol. 1999 Aug;34(2):318-24 [10440139.001]
  • (PMID = 20694854.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 63X7MBT2LQ / Bucladesine; 9LHU78OQFD / Lovastatin; E0399OZS9N / Cyclic AMP; EC 1.14.16.2 / Tyrosine 3-Monooxygenase
  •  go-up   go-down


12. Genc H, Haciyanli M, Haciyanli SG, Gelal F, Avci Uçarsoy A, Dag F: An adult adrenal neuroblastoma: a case report. Acta Chir Belg; 2005 Nov-Dec;105(6):673-6
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An adult adrenal neuroblastoma: a case report.
  • Neuroblastoma of the adrenal gland is an extremely rare tumour in adulthood although it is one of the most common malignancies in childhood.
  • He was operated and the mass was resected in en-block manner along with the regional lymph nodes.
  • The histopathological examination of the specimen revealed the diagnosis of neuroblastoma.
  • He had no metastatic disease at the time of diagnosis and received chemotherapy after the operation.
  • Although neuroblastoma of adrenal gland is rare in adulthood, it should be considered in the differential diagnosis for patients with adrenal masses.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Neuroblastoma / diagnosis
  • [MeSH-minor] Adrenalectomy. Chemotherapy, Adjuvant. Fatal Outcome. Humans. Liver Neoplasms / secondary. Male. Metanephrine / urine. Middle Aged. Vanilmandelic Acid / urine

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438086.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 5001-33-2 / Metanephrine; 55-10-7 / Vanilmandelic Acid
  •  go-up   go-down


13. Fukushima T, Shichino H, Kumagai M: [Neuroblastoma trial to overcome a rare malignant disease]. Gan To Kagaku Ryoho; 2007 Feb;34(2):167-74
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroblastoma trial to overcome a rare malignant disease].
  • Neuroblastoma is one of the main causes of children's deaths in Japan and many developed countries, although it is a rather rare pediatric cancer.
  • In Japan, the main hospitals, where clinical study including clinical trials have been conducted, are not only national centers but also many regional or prefectural centers.
  • These are the same as the outcomes of neuroblastoma patients in European countries and North America.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Neuroblastoma / therapy. Rare Diseases
  • [MeSH-minor] Child. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Transplantation, Autologous

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301522.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Paulino AC, Mayr NA, Simon JH, Buatti JM: Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys; 2002 Mar 15;52(4):1025-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity.
  • PURPOSE: To review patterns of failure in infants with neuroblastoma and determine late toxicity and efficacy of radiotherapy (RT) on locoregional control.
  • MATERIALS AND METHODS: From 1955 to 1998, 53 children (35 males and 18 females) <1 year old with neuroblastoma were seen at our institution.
  • All infants were retrospectively staged according to the International Neuroblastoma Staging System (INSS); 8 had Stage 1, 7 Stage 2A, 6 Stage 2B, 15 Stage 3, 6 Stage 4, and 11 Stage 4S.
  • Sixteen infants had pathologic involvement of regional lymph nodes (LN+).
  • Fifteen received RT to the primary site and regional nodes (postoperative 8, preoperative 7).
  • Postoperative doses ranged from 15 to 25 Gy whereas preoperative doses ranged from 12 to 31 Gy using a median fraction size of 1.5 Gy.
  • Chemotherapy was employed in 22 of 53 patients (42%) with the most common agents being cyclophosphamide in 22 and doxorubicin in 11.
  • Five of 6 infants <6 months of age and 1 of 7 >/=6 months developed musculoskeletal toxicity.
  • Musculoskeletal effects were seen in 6 RT patients and included bony hypoplasia in 6, scoliosis in 5, soft tissue hypoplasia in 3, slipped capital femoral epiphysis in 2, kyphosis in 1, and osteochondroma in 1.
  • Three required orthopedic intervention, all receiving >/=20 Gy.
  • One child developed bowel obstruction at 21 months and another developed a leiomyosarcoma in the treatment field 34 years after RT.
  • Further studies are needed to determine if cardiovascular anomalies are more frequently seen in children with neuroblastoma.
  • [MeSH-major] Neuroblastoma / radiotherapy
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / pathology. Abdominal Neoplasms / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Infant, Newborn. Lymphatic Metastasis. Male. Musculoskeletal Diseases / etiology. Neoplasm Staging. Pelvic Neoplasms / mortality. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Radiation Injuries / complications. Survival Rate. Thoracic Neoplasms / mortality. Thoracic Neoplasms / pathology. Thoracic Neoplasms / radiotherapy. Treatment Failure

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1575; author reply 1575 [12459387.001]
  • (PMID = 11958898.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Wolden SL, Gollamudi SV, Kushner BH, LaQuaglia M, Kramer K, Rosen N, Abramson S, Cheung NV: Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys; 2000 Mar 1;46(4):969-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control with multimodality therapy for stage 4 neuroblastoma.
  • PURPOSE: To evaluate the efficacy of 21 Gy hyperfractionated radiotherapy for local control in conjunction with surgery and intensive systemic therapy for patients with Stage 4 neuroblastoma.
  • METHODS AND MATERIALS: After achieving a partial or complete remission, 47 children, ages 1-10 years, with Stage 4 neuroblastoma were treated on four consecutive institutional protocols (N4-N7) with dose-intensive multi-agent chemotherapy, maximal surgical debulking, and hyperfractionated radiotherapy (1.5 Gy twice a day to 21 Gy).
  • Radiotherapy fields encompassed the initial tumor volume and regional lymph nodes plus a 3-cm margin.
  • RESULTS: Forty-five of 47 patients had a complete response to surgery and chemotherapy prior to radiotherapy.
  • Among 26 patients who relapsed, 1 failed only at the primary site, 22 developed distant metastases exclusively, and 3 had both local and distant failures.
  • CONCLUSION: Hyperfractionated radiotherapy to 21 Gy, in conjunction with dose-intensive systemic therapy and aggressive surgical resection, is well tolerated and is associated with durable local control for most patients with Stage 4 neuroblastoma.
  • [MeSH-major] Neuroblastoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasm, Residual

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10705019.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


16. Kushner BH, LaQuaglia MP, Kramer K, Cheung NK: Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol; 2004 Jan;26(1):35-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.
  • Neuroblastoma risk stratification is based on stage, age, and biology and prescribes surgery for low-risk disease, moderate-dose chemotherapy for intermediate-risk disease, and maximal therapy (including myeloablative treatment with stem cell transplantation) for high-risk disease.
  • Stage was defined by the International Neuroblastoma Staging System.
  • The first recommendations were for maximal therapy, but second opinions were radically different (ie, surgery alone).
  • All four patients did well without cytotoxic therapy (follow-up: 2 years 10 months plus to 4 years 8 months plus).
  • Biopsies of the latter showed no neuroblastoma and the primary tumor (with regional lymph nodes) was resected, changing stage from 4 to 2B.
  • Patient 4 had a pelvic mass, with unfavorable histopathology, and bilateral inguinal lymph node involvement (stage 3); all soft tissue disease was resected.
  • The absence of cortical bone and extensive bone marrow metastatic involvement in a young neuroblastoma patient should cause a shift in attention to biologic prognostic markers.
  • Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy.
  • [MeSH-major] Health Planning Guidelines. Neuroblastoma / diagnosis. Neuroblastoma / surgery
  • [MeSH-minor] Biomarkers / analysis. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707711.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


17. Park JR, Slattery J, Gooley T, Hawkins D, Lindsley K, Villablanca JG, Matthay KK, Sanders JE: Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol; 2000 Dec;35(6):719-23
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
  • We evaluated the toxicity and maximum tolerated dose of topotecan in a novel myeloablative regimen as treatment for high-risk pediatric tumors.
  • We describe preliminary results following treatment of 25 pediatric patients with high-risk solid tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glioma / drug therapy. Neuroblastoma / drug therapy. Topotecan / therapeutic use
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans. Infant. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11107155.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


18. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F: Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol; 2008 Mar 20;26(9):1504-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The excellent prognosis of localized neuroblastoma in infants, the overdiagnosis observed in neuroblastoma screening studies, and several case reports of regression of localized neuroblastoma prompted us to initiate a prospective cooperative trial on observation of localized neuroblastoma without cytotoxic treatment.
  • PATIENTS AND METHODS: For infants with localized neuroblastoma without MYCN amplification, chemotherapy was scheduled only in cases with threatening symptoms; otherwise, the tumor was either resected or observed by ultrasound and magnetic resonance imaging (MRI).
  • RESULTS: Of 340 eligible participants, 190 underwent resection, 57 were treated with chemotherapy, and 93 were observed with gross residual tumor.
  • Time to regression was quite variable, with first signs of regression noted 1 to 18 months after diagnosis and in 15 of 44 patients even after the first year of life.
  • Known clinical risk factors were not able to differentiate between patients with regression and regional or metastatic progression.
  • Overall survival (OS; 3-year OS, 0.99 +/- 0.01) and metastases-free survival (rate at 3 years, 0.94 +/- 0.03) for patients with unresected tumors was excellent and was not different from patients treated with surgery or chemotherapy.
  • CONCLUSION: Spontaneous regression is regularly seen in infants with localized neuroblastoma and is not limited to the first year of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Regression, Spontaneous. Neuroblastoma / diagnosis

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002803/ NCT00017225
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G: Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2006 Nov;47(6):790-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: Patients with Ewing sarcoma family of tumors (ESFT), osteosarcoma (OS), soft tissue sarcomas (STS), medulloblastoma (MB)/primitive neuroectodermal tumor (PNET), astrocytoma, or neuroblastoma (NB) recurrent or refractory to conventional therapy, measurable disease, and adequate organ function were treated with topotecan 0.3 mg/m2/day by continuous intravenous infusion for 21 consecutive days, followed by 7 days without therapy prior to response assessment.
  • RESULTS: Fifty-five patients were enrolled; two were ineligible, two were removed from protocol therapy prior to evaluation for response, and one was inevaluable for response, leaving 53 and 50 patients evaluable for toxicity and response, respectively.
  • The most common Grade 3 or 4 toxicities during the first course of therapy were thrombocytopenia (12/53), neutropenia (8/53), and fatigue (7/53).
  • [MeSH-major] Astrocytoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neuroblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Sarcoma / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Fatigue / chemically induced. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Neutropenia / chemically induced. Recurrence. Survival Rate. Thrombocytopenia / chemically induced. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16435380.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan
  •  go-up   go-down


20. Schmidt M, Schler G, Gruensfelder P, Hoppe F: Differential gene expression in a paclitaxel-resistant clone of a head and neck cancer cell line. Eur Arch Otorhinolaryngol; 2006 Feb;263(2):127-34
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anti-neoplastic drug paclitaxel (taxol), which is known to block cells in the G2/M phase of the cell cycle through stabilization of microtubules, is meanwhile commonly used for chemotherapy of advanced head and neck cancer.
  • Chemotherapy is primarily used in order to preserve laryngeal and/or pharyngeal structures.
  • Although paclitaxel generally seems to be a powerful agent, it failed to reach a loco-regional tumor control in a sufficient percentage of patients.
  • We used western blotting and the cDNA subtraction (SSH) technique to identify genes differentially expressed in the taxol-resistant cell clone. cDNA subtraction revealed increased expression of six genes, including clathrin heavy chain, alpha3-tubulin, a neuroblastoma-specific Thymosin beta, the ribosomal protein L7a, HLA-B associated transcript 3 and collagen IIIalpha1 in the taxol-resistant cell line.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Blotting, Western. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. Drug Resistance, Neoplasm / genetics. Humans. Paclitaxel / therapeutic use. Tubulin Modulators / therapeutic use

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1998 Nov;186(3):262-8 [10211114.001]
  • [Cites] Oncologist. 2000;5(3):199-208 [10884498.001]
  • [Cites] Arch Otorhinolaryngol. 1979;225(4):269-77 [548013.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):757-62 [10717245.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 12;287(5):1075-82 [11587531.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):878-84 [11895922.001]
  • [Cites] Radiother Oncol. 2003 Aug;68(2):163-70 [12972311.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(12):1565-71 [10930805.001]
  • [Cites] Oncogene. 2004 Aug 26;23 (39):6666-71 [15235586.001]
  • [Cites] Methods Cell Sci. 2000 Mar;22(1):63-6 [10650336.001]
  • [Cites] Nat Med. 1996 Dec;2(12):1322-8 [8946830.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):823-8 [9485041.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 1;128(1):1-6 [11454421.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4287-300 [12833151.001]
  • [Cites] J Biochem Biophys Methods. 1984 Dec;10(3-4):203-9 [6530509.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6540-7 [11522652.001]
  • [Cites] Respiration. 2003 Jan-Feb;70(1):32-5 [12584388.001]
  • [Cites] Semin Cancer Biol. 1997 Jun;8(3):135-42 [9441943.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):27-32 [9724090.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Apr;119(4):411-4 [8096141.001]
  • [Cites] Biochemistry. 2003 May 13;42(18):5349-57 [12731876.001]
  • [Cites] Am J Physiol. 1997 Aug;273(2 Pt 1):C687-702 [9277367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11358-62 [7972064.001]
  • [Cites] J Natl Cancer Inst Monogr. 1993;(15):55-61 [7912530.001]
  • [Cites] DNA Res. 1996 Oct 31;3(5):311-20 [9039501.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):182-3 [10655426.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):433-73 [12663865.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Jpn J Cancer Res. 2002 Nov;93(11):1230-6 [12460464.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1207-13 [12649178.001]
  • [Cites] Cancer Lett. 2000 Aug 11;156(2):191-8 [10880769.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):8031-41 [12970751.001]
  • (PMID = 16380805.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IRF9 protein, human; 0 / Interferon-Stimulated Gene Factor 3, gamma Subunit; 0 / RNA, Neoplasm; 0 / Tubulin; 0 / Tubulin Modulators; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Singh G, Espiritu M, Shen XY, Hanlon JG, Rainbow AJ: In vitro induction of PDT resistance in HT29, HT1376 and SK-N-MC cells by various photosensitizers. Photochem Photobiol; 2001 Jun;73(6):651-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our approach to examine the mechanism(s) of action for photodynamic therapy (PDT) has been via the generation of PDT-resistant cell lines.
  • In this study we used three human cell lines, namely, human colon adenocarcinoma (HT29), human bladder carcinoma and human neuroblastoma.
  • The protocol for inducing resistance consisted of repeated in vitro photodynamic treatments with a photosensitizer to the 1-10%-survival level followed by regrowth of single surviving colonies.
  • [MeSH-minor] Cell Survival / drug effects. Drug Resistance. HT29 Cells. Humans. Photobiology. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11421071.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 43892
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


22. Pein F, Pinkerton R, Berthaud P, Pritchard-Jones K, Dick G, Vassal G: Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours. Eur J Cancer; 2007 Sep;43(14):2074-81
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PSC 833 is an effective MDR1 reversal agent in vitro, including studies with paediatric cancer cell lines such as neuroblastoma and rhabdomyosarcoma.
  • Neuroblastoma and rhabdomyosarcoma were the common disease types.
  • Three patients developed grade 3 neurotoxicity in the 6 mg/kg cohort and this defined the MTD.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cyclosporins / administration & dosage. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Ataxia / chemically induced. Child. Child, Preschool. Cohort Studies. Dose-Response Relationship, Drug. Feasibility Studies. Female. Gastrointestinal Diseases / chemically induced. Humans. Infant. Infusions, Intravenous. Male. Maximum Tolerated Dose

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17716890.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclosporins; 121584-18-7 / valspodar; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


23. Tímár J, Nemzeti Onkológiai Kutatás-fejlesztési Konzorcium: [Activity of the National Oncology R&D Consortium in 2004]. Magy Onkol; 2005;49(1):3-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have prepared the map of regional distribution of cervical cancer in Hungary.
  • We have introduced a cost-effective in vitro assay to determine the drug resistance of pediatric leukemias.
  • The prognostic power of N-myc genotyping was determined in neuroblastoma patients.
  • A phase I trial for gene therapy of brain cancer was started by using a GM-CSF adenoviral vector system.
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Breast Neoplasms / genetics. Breast Neoplasms / therapy. Colonic Neoplasms / diagnosis. Colonic Neoplasms / epidemiology. Colonic Neoplasms / genetics. Colonic Neoplasms / therapy. Disease Progression. Female. Government Agencies. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / therapy. Humans. Hungary. Journalism, Medical. Male

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902326.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Hungary
  • [Number-of-references] 32
  •  go-up   go-down


24. Gow KW, Lensing S, Hill DA, Krasin MJ, McCarville MB, Rai SN, Zacher M, Spunt SL, Strickland DK, Hudson MM: Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature. J Pediatr Surg; 2003 Nov;38(11):1574-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature.
  • METHODS: The authors reviewed the medical records of 8 children with PTM and 17 children with STM referred to St Jude Children's Research Hospital between February 1962 and February 2002 for evaluation and treatment of malignant thyroid carcinoma.
  • Three of the 8 (37.5%) had metastatic disease involving regional lymph nodes; 2 patients (25.0%) had lung metastases.
  • Seventeen patients had thyroid carcinoma as a second malignant neoplasm after treatment for acute lymphoblastic leukemia (n = 6), Hodgkin's disease (n = 5), central nervous system tumor (n = 2), Wilms' tumor (n = 1), retinoblastoma (n = 1), non-Hodgkin's lymphoma (n = 1), or neuroblastoma (n = 1).
  • Twelve of the 17 patients (70.6%) had received radiation to the thyroid gland during therapy for the primary cancer.
  • Four patients (23.5%) had metastatic disease involving regional lymph nodes.
  • At the time of this report, all 17 patients are alive and in continue to be free of disease.
  • CONCLUSIONS: Pediatric thyroid carcinoma is uncommon and responds well to current therapy.
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasms / drug therapy. Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / epidemiology. Retrospective Studies. Tennessee / epidemiology. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614703.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Number-of-references] 49
  •  go-up   go-down






Advertisement